Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDL Cardiol Therapeutics Inc

Closed Good Friday 04-17 16:00:00 EDT

1.01

+0.00

0.00%

盘后0.9650

-0.05-4.46%

19:54 EDT

High1.05	Low0.9593	Vol124.72K
Open1.02	D1 Closing1.01	Amplitude8.98%
Mkt Cap83.44M	Tradable Cap79.49M	Total Shares82.61M
T/O123.85K	T/O Rate0.16%	Tradable Shares78.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CRDL","market":"US","secType":"STK","nameCN":"Cardiol Therapeutics Inc","latestPrice":1.01,"timestamp":1744920000000,"preClose":1.01,"halted":0,"volume":124722,"hourTrading":{"tag":"盘后","latestPrice":0.965,"preClose":1.01,"latestTime":"19:54 EDT","volume":206,"amount":198.8475,"timestamp":1744934049720},"delay":0,"floatShares":78707542,"shares":82608992,"eps":-0.356178,"marketStatus":"Closed Good Friday","change":0,"latestTime":"04-17 16:00:00 EDT","open":1.02,"high":1.05,"low":0.9593,"amount":123849.11312748,"amplitude":0.089802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.356178,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.01,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":1.01,"latestTime":"08:00 EDT","volume":6,"amount":6.12,"timestamp":1744891205846},"postHourTrading":{"tag":"盘后","latestPrice":0.965,"preClose":1.01,"latestTime":"19:54 EDT","volume":206,"amount":198.8475,"timestamp":1744934049720},"volumeRatio":0.7974521846560431,"impliedVol":1.7565,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/CRDL","defaultTab":"news","newsList":[{"id":"2528238016","title":"Cardiol Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2528238016","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528238016?lang=en_us&edition=full_marsco","pubTime":"2025-04-19 04:02","pubTimestamp":1745006542,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Cardiol Therapeutics Inc CRDL.TO  is expected to show no change in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nL8N3QW0R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2527329076","title":"Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis","url":"https://stock-news.laohu8.com/highlight/detail?id=2527329076","media":"Newsfile","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527329076?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 19:27","pubTimestamp":1744802820,"startTime":"0","endTime":"0","summary":"Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.Recurrent pericarditis is a debilitating heart condition that results in chest pain, shortness of breath and fatigue, physical limitations, reduced quality of life, and hospitalizations.CardiolRx, which has been granted US FDA Orphan Drug Designation for this indication, is a small molecule oral drug targeting inflammasome ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-enrolls-first-patient-112700134.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-enrolls-first-patient-112700134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","LENZ","BK4139","BK4007","BK4134","III"],"gpt_icon":0},{"id":"2526840408","title":"Cardiol Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840408?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 04:12","pubTimestamp":1744143127,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Cardiol Therapeutics Inc CRDL.TO  is expected to show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL5N3QM1RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2524418336","title":"Cardiol Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524418336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524418336?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 23:17","pubTimestamp":1743607036,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryCardiol Therapeutics Inc CRDL.TO reported a quarterly adjusted loss of 9 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nL5N3QG19Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2524413918","title":"We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524413918","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524413918?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:26","pubTimestamp":1743596818,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So should Cardiol Therapeutics  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.Does Cardiol Therapeutics Have A Long Cash Runway?Check out our latest analysis for Cardiol Therapeutics. Since it has a market capitalisation of CA$112m, Cardiol Therapeutics' CA$25m in cash burn equates to ab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-cardiol-therapeutics-122658065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CRDL","BK4090","TSE"],"gpt_icon":0},{"id":"2524114757","title":"Cardiol Therapeutics Announces Year-End 2024 Update on Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2524114757","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524114757?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:27","pubTimestamp":1743506820,"startTime":"0","endTime":"0","summary":"Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial. Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx in patientswith acute myocarditis, with topline data expected in Q2 2025. CardiolRx granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditis. Cash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026. In February 2024, CardiolRx was granted Orphan Drug Designation by the United States Food and Drug Administration for the treatment of pericarditis, which includes recurrent pericarditis. Pericarditis refers to inflammation of the pericardium  frequently resulting from a viral infection. Following that initial episode patients may have multiple recurrences, and the primary goal of treatment is rec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-end-2024-112700396.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-end-2024-112700396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2523384156","title":"Cardiol Therapeutics Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523384156","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523384156?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 04:31","pubTimestamp":1743193867,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc  expected to post a loss of12cents a share - Earnings Preview Cardiol Therapeutics Inc CRDL.TO  is expected to show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","PVLA","SDST","CELC","KYTX","PENG","CLSD","SKYH","RANI","FBIO","ADCT","PRGS","LULU","RLMD","FEMY","BRZE","TSAT","AFMD","WGO","ANGO","ATAI","SLRN","CALC","GWH","FTCI","LNZA","MDAI","BHST","EDAP","SPWH","UNCY","IKT","INMB","FC","BW","NCNO","DARE","PVH","WBA","SGML","NUTX","GEVO","GOVX","INR","CRDL","NNOX","TLSI","WKSP","BCAB","REKR"],"gpt_icon":0},{"id":"2516993638","title":"Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516993638","media":"Newsfile","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516993638?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:27","pubTimestamp":1741004820,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Cardiol Therapeutics Inc.   , a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.Cardiol Therapeutics Inc.   is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx  oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol modulates activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.Cardiol is also developing CRD-38, a nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-present-td-cowen-122700227.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-present-td-cowen-122700227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","BK4139","COWN","BK4566","TD","BK4207","BK4585","BK4127","BK4007","LENZ"],"gpt_icon":0},{"id":"2512441469","title":"Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2512441469","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512441469?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 20:27","pubTimestamp":1740054420,"startTime":"0","endTime":"0","summary":"Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure. These newly published data demonstrate that pharmaceutically manufactured cannabidiol, administered subcutaneously, provides cardioprotection in a pre-clinical model of heart failure by improving cardiac function and reducing cardiac hypertrophy, remodeling, inflammation, and cell death, and provides additional important rationale for the development of CRD-38 as a new approach to the treatment of heart failure.The JACBTS publication comprises results from multiple models of heart failure:. an in vivo model of angiotensin II-induced heart failure. SubQ administration resulted in attenuation of cardiac fibrosis,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-publication-research-122700956.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-publication-research-122700956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4117","BAS","BK4107","CRDL","BK4139","AFG","LENZ"],"gpt_icon":0},{"id":"2508119634","title":"Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol","url":"https://stock-news.laohu8.com/highlight/detail?id=2508119634","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508119634?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 17:09","pubTimestamp":1738573740,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR and Cardiol Therapeutics CRDL.The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency that oversees the FDA. Trump is expected to make significant changes at all major healthcare agencies. Regular pipeline setbacks, the slow ramp-up of newer drugs, patent cliffs, regulatory risks and macroeconomic pressure are some other headwinds for the sector.Innovation is at its peak for the industry, with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention. R&D innovation is likely to remain a major focus area in 2025 as well. These factors should continue to drive stocks like Corcept Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-industry-outlook-highlights-corcept-090900450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".SPX","SDS","VOO","ESmain","BK4581","SH","BK4007","BK4532","AMRX","DYN","CORT","IVV","BK4550","SPY","BK4505","BK4585","BK4588","BK4139","BK4534","LU0566484027.USD","LU1559883803.SGD","BK4559","BK4504","CRDL","OEF","UPRO","NKTR","OEX","SPXU","SSO"],"gpt_icon":0},{"id":"2507796377","title":"5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era","url":"https://stock-news.laohu8.com/highlight/detail?id=2507796377","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507796377?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 21:03","pubTimestamp":1738328580,"startTime":"0","endTime":"0","summary":"The ZacksMedical-Drugsindustry comprises small and some medium-sized drug companies that make medicines for both human and veterinary use. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial-stage drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate. For such companies, upfront or milestone payments from collaboration partners — in most cases, their larger counterparts — are the main sources of revenues. These companies need ample free cash flow to fund their R&D activities.Factors Shaping the Future of the Medical-Drugs Industry. Investment in Technology for Innovation: For smaller companies, succeeding in a shifting global market and evolving healthcare landscape requires adopting innovative business models, investing in new technologies and increasing investments in personalized medicines. Over the past few years, scientific and technological advancements","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-small-drug-stocks-add-130300236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CORT","AMRX","DYN","NKTR","BK4532","SDS","UPRO","BK4559","SSO","SPY","OEF","BK4550","LU1559883803.SGD","BK4505","BK4007","BK4504","VOO",".SPX","CRDL","ESmain","SPXU","BK4534","OEX","LU0566484027.USD","BK4585","BK4581","IVV","SH","BK4588"],"gpt_icon":0},{"id":"2484608025","title":"Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484608025","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484608025?lang=en_us&edition=full_marsco","pubTime":"2024-11-19 00:37","pubTimestamp":1731947820,"startTime":"0","endTime":"0","summary":"Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study. MAvERIC-Pilot results support advancing CardiolRx into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials. The MAvERIC-Pilot study enrolled 27 participants  at eight clinical sites across the United States. Average disease duration and the number of pericarditis episodes per year prior to trial entry were 2.7 years and 5.8 events per year, respectively. Baseline pericarditis pain score averaged 5.8 out of 10 and the C-reactive protei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SNLatFs9t095hO6ZfF5o6Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/5649ee63ca7bc5515f8119ab3d294731","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SNLatFs9t095hO6ZfF5o6Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/5649ee63ca7bc5515f8119ab3d294731"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-phase-ii-maveric-163700007.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-phase-ii-maveric-163700007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","LENZ","BK4139","BK4007","BK4107","BK4117","CRDL"],"gpt_icon":1},{"id":"2483085371","title":"Cardiol Therapeutics Inc reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483085371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483085371?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 22:03","pubTimestamp":1731679396,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc reports results for the quarter  - Earnings SummaryCardiol Therapeutics Inc CRDL.TO reported a quarterly adjusted loss of 18 cents per share for the quarter , lower than the s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL8N3MM15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2483789002","title":"Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2483789002","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483789002?lang=en_us&edition=full_marsco","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases. NEW YORK, Nov. 13, 2024  -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc.  has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx, positions it as a pioneer in addressing major unmet needs in cardiac care.Recurrent pericarditis affects approximately 38,000 patients in the United States annually who have experienced at least one recurrence. The global pericarditis market was valued at $2.44 billion in 2023 and is projected to grow at a CAGR of 5.24% during the forecast period of 2024-2032, reaching $3.87 billion by 2032.In addition, Cardiol is advancing CRD-38, a proprietary subcutaneously","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4mLU.0ORbBAziimH5lwK5w--~B/aD0xNTAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/371a8f2aeb61f9794e5eaec23621376a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4mLU.0ORbBAziimH5lwK5w--~B/aD0xNTAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/371a8f2aeb61f9794e5eaec23621376a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-inc-added-prism-130000195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CRDL"],"gpt_icon":1},{"id":"2482420129","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2482420129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482420129?lang=en_us&edition=full_marsco","pubTime":"2024-11-11 19:00","pubTimestamp":1731322800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Angi Inc Class A                                3Q       .00       AMC. ·Global Ship Lease                                3Q      2.41   8:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAE","ICL","NOTE","TWKS","ABSI","CYTH","FBRX","CRVO","CNTA","EARN","CCLD","XP","FLNG","CNNE","AMTX","RVPH","DHT","DDI","DAVA","TSVT","DHX","NRGV","ATER","BLFS","OBIO","GAUZ","CHGG","XGN","MLYS","IKT","CRDL","ASRT","CLRB","IAC","LAZR","INTS","AVTE","AXSM","GENI","SGMT","DAVE","GATO","ABOS","EQ","ARMK","AZN","FTCI","FIHL","ATAI","KEP"],"gpt_icon":0},{"id":"2482745272","title":"Cardiol Therapeutics Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482745272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482745272?lang=en_us&edition=full_marsco","pubTime":"2024-11-09 06:20","pubTimestamp":1731104421,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc  expected to post a loss of11cents a share - Earnings Preview Cardiol Therapeutics Inc CRDL.TO  is expected to show no change in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF41J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2477135974","title":"Are Medical Stocks Lagging  Cardiol Therapeutics (CRDL) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477135974","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477135974?lang=en_us&edition=full_marsco","pubTime":"2024-10-22 21:40","pubTimestamp":1729604413,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Cardiol Therapeutics Inc.  one of those stocks right now?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cardiol Therapeutics Inc. is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cardiol Therapeutics Inc. is currently sporting a Zacks Rank of #2 .Another Medical","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-cardiol-therapeutics-134013393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","CRDL","BK4588","BK4530","CTLT"],"gpt_icon":0},{"id":"2477438145","title":"Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis","url":"https://stock-news.laohu8.com/highlight/detail?id=2477438145","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477438145?lang=en_us&edition=full_marsco","pubTime":"2024-10-22 18:30","pubTimestamp":1729593000,"startTime":"0","endTime":"0","summary":"MAVERIC-2 trial will evaluate the impact of CardiolRx following cessation of interleukin-1 blocker therapy  and is expected to run concurrently with the Company's planned Phase III program.IL-1 is a key pro-inflammatory cytokine in the pathophysiology of recurrent pericarditis. It is generated downstream following activation of the NLRP3 inflammasome and amplifies the autoinflammatory response characteristic of the disease. IL-1 blockers  target and negate the activity of IL-1, but given their expense and immunosuppressant risks, they are generally prescribed as a third-line intervention in difficult-to-treat patients. There is a growing body of evidence indicating pericarditis recurrence rates are as high as seventy-five percent and onset is rapid following cessation of IL-1 blocker thera","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lX.QzNqzG.VIVWVm.XSEnQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/d68c2d33547d61f2e98b3e3432e19738","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lX.QzNqzG.VIVWVm.XSEnQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/d68c2d33547d61f2e98b3e3432e19738"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-advance-cardiolrx-tm-103000954.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-advance-cardiolrx-tm-103000954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["03160","BK4099","TM","SSI","BK4588","LENZ","CRDL","BK4007","BK4555","BK4585","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiolrx.com","stockEarnings":[{"period":"1week","weight":0.1272},{"period":"1month","weight":-0.0982},{"period":"3month","weight":-0.1653},{"period":"6month","weight":-0.474},{"period":"1year","weight":-0.4229},{"period":"ytd","weight":-0.2109}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.232353},{"month":2,"riseRate":0.25,"avgChangeRate":0.041331},{"month":3,"riseRate":0,"avgChangeRate":-0.11215},{"month":4,"riseRate":0.75,"avgChangeRate":0.079717},{"month":5,"riseRate":0.666667,"avgChangeRate":0.123182},{"month":6,"riseRate":0.333333,"avgChangeRate":0.025449},{"month":7,"riseRate":0.666667,"avgChangeRate":0.094263},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.078283},{"month":9,"riseRate":0.5,"avgChangeRate":-0.034119},{"month":10,"riseRate":0,"avgChangeRate":-0.177472},{"month":11,"riseRate":0.25,"avgChangeRate":-0.145686},{"month":12,"riseRate":0,"avgChangeRate":-0.093785}],"exchange":"NASDAQ","name":"Cardiol Therapeutics Inc","nameEN":"Cardiol Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiol Therapeutics Inc(CRDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiol Therapeutics Inc,CRDL,Cardiol Therapeutics Inc股票,Cardiol Therapeutics Inc股票老虎,Cardiol Therapeutics Inc股票老虎国际,Cardiol Therapeutics Inc行情,Cardiol Therapeutics Inc股票行情,Cardiol Therapeutics Inc股价,Cardiol Therapeutics Inc股市,Cardiol Therapeutics Inc股票价格,Cardiol Therapeutics Inc股票交易,Cardiol Therapeutics Inc股票购买,Cardiol Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiol Therapeutics Inc(CRDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction